Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's core scientific strategy centers on designing orally delivered, small-molecule therapies that target G-protein coupled receptors (GPCRs) to replace burdensome, chronically injected peptide regimens. Its flagship product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA and the European Medicines Agency (EMA) for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. Beyond acromegaly, Crinetics is advancing a robust pipeline of over 10 programs, including its second late-stage investigational candidate, atumelnant, an oral ACTH receptor antagonist in development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.

Research as of 19 Jun 2026